HENDERSON, NV / ACCESSWIRE / April 18, 2023 / Movella Holdings Inc. (NASDAQ: MVLA) (‘Movella'), a global leader in the digitization of movement, is providing critical technology to researchers tracking the onset of diseases that impair movement. Movella's Xsens motion capture technology is being used in medical research to develop new examination methodologies and treatments.
Researchers at Imperial College and University College London, led by Professor Aldo Faisal, have spent seven years conducting in-depth studies into the progression of Friedreich's Ataxia (FA) and Duchenne Muscular Dystrophy (DMD). The use of Xsens motion capture allows for quick and accurate assessments of a patient's movement, detecting subtle motions that human analysis alone cannot.
The FA and DMD studies, published in the journal Nature Medicine, demonstrate the effectiveness of motion capture data in predicting the worsening of degenerative nerve conditions. Assessing the efficacy of a movement-enhancing drug often involves patients who find walking difficult for extended periods of time. Through analysis of digitized movement data generated by the Xsens suit, this burden is minimized to a matter of steps, allowing medical professionals to predict the progression of these diseases in half the time it would normally take.
"We believe that the application of Movella's technology has the potential to change the economics of drug discovery," said Dr Aldo Faisal, Professor of AI and Neuroscience for Imperial College London. "With motion capture, we have been able to create an entirely new field of study: ethomics. It will attract the pharmaceutical industry to invest in rare diseases, but the main beneficiary from our research is going to be patients. The technology is going to be able to come up with all new treatments faster."
"The impact motion capture will have on developing new drugs and diagnoses for a range of diseases will be huge," says CJ Hoogsteen, VP Sales & Marketing at Movella. "Through the use of Movella's Xsens solutions, medical professionals can reduce the time and cost required to develop new drugs in clinical trials and make it more cost-effective to test new drugs for rare genetic disorders."
The team is already seeking approval for the use of Movella's solutions in clinical drug trials, beginning in two years. Additional research into Parkinson's, Alzheimer's, and MS are now taking place.
Photo credits: Thomas Angus, Imperial College
About Movella Holdings Inc.
Movella is a leading full-stack provider of sensors, software, and analytics that enable the digitization of movement. Movella serves the entertainment, health & sports, and automation & mobility markets. Our innovations enable customers to capitalize on the value of movement by transforming data into meaningful and actionable insights. Partnering with leading global brand such as Electronic Arts, EPIC Games, 20th Century Studios, Netflix, Toyota, Siemens and over 500 sports organizations, Movella is creating extraordinary outcomes that move humanity forward. To learn more, please visit www.movella.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of federal securities laws. The words "accelerate," "anticipate," "believe," "continue," "could," "enable," "estimate," "expect," "extend," "fuel," "future," "growth," "intend," "may," "might," "opportunity," "outlook," "plan," "position," "possible," "potential," "predict," "progress," "project," "realize," "see," "seem," "should," "will," "would," and similar expressions, or the negative of such expressions, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the following: Movella's management team's expectations, hopes, beliefs, intentions or strategies regarding the future and the company's competitive position; the potential impact of the merger on Movella and its business, including allowing Movella to continue to rapidly scale its business and further invest in market-leading movement capture and digitization solutions; the potential benefits and expectations related to the terms of the FP financing, including but not limited to, the sale of FP-purchased stock and repayment of the note; the ability of Movella's solutions to enable real-time digitized movement in the emerging high-growth areas of the Metaverse, next-generation gaming, live streaming and other applications; the anticipated use of capital raised from the transaction to further scale and grow the business; the belief that Movella's proprietary technology, scalable business model, and experienced leadership team will position Movella to extend its leadership position and continue to deliver innovations that drive the industry; the anticipated or potential features, benefits, and applications for Movella's products and technology and timing thereof; the market opportunity for Movella's products and technology; or other characterizations of future events or circumstances, including any underlying assumptions. These statements are based on the current expectations of Movella's management and are not predictions of actual performance and as such, are provided for illustrative purposes only. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Movella's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: (i) failure to realize the anticipated benefits of the merger ; (ii) general economic conditions and Movella's financial performance; (iii) changes adversely affecting the businesses in which Movella is engaged; (iv) Movella's ability to execute on its business strategy and plans and to manage growth; and (v) risks related to regulatory matters, as well as the factors described under the headings "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the final prospectus filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 424(b)(3) by Pathfinder on January 17, 2023 and in those documents that Movella will file with the SEC in the future. If any of these risks materialize or the underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Movella presently knows or currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect expectations, plans or forecasts of future events and views as of the date of this press release. Movella anticipates that subsequent events and developments will cause its assessments to change. However, while Movella may elect to update these forward-looking statements at some point in the future, Movella specifically disclaims any obligation to do so, except to the extent required by applicable law. These forward-looking statements should not be relied upon as representing Movella's assessments as of any date subsequent to the date of this press release and are not intended to serve as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Accordingly, undue reliance should not be placed upon the forward-looking statements.